Summary
2.51 0.03(1.01%)10/04/2024
AbCellera Biologics Inc (ABCL)
AbCellera Biologics Inc (ABCL)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 1.21 | -3.84 | -0.60 | -6.88 | -43.07 | -43.45 | 0.00 | -95.75 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 2.51 | |
| Open | 2.51 | |
| High | 2.55 | |
| Low | 2.45 | |
| Volume | 1,030,111 | |
| Change | 0.03 | |
| Change % | 1.21 | |
| Avg Volume (20 Days) | 1,676,925 | |
| Volume/Avg Volume (20 Days) Ratio | 0.61 | |
| 52 Week Range | 2.34 - 6.05 | |
| Price vs 52 Week High | -58.60% | |
| Price vs 52 Week Low | 7.05% | |
| Range | -0.20 | |
| Gap Up/Down | 0.01 | |
Fundamentals | ||
| Market Capitalization (Mln) | 754 | |
| EBIDTA | 298,535,008 | |
| PE Ratio | 20.4348 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 41.50 | |
| Book Value | 3.3910 | |
| Earnings Per Share | 0.6440 | |
| EPS Estimate Current Quarter | -0.0400 | |
| EPS Estimate Next Quarter | -0.0500 | |
| EPS Estimate Current Year | 0.4900 | |
| EPS Estimate Next Year | -0.1300 | |
| Diluted EPS (TTM) | 0.6440 | |
| Revenues | ||
| Profit Marging | 0.4744 | |
| Operating Marging (TTM) | 0.6434 | |
| Return on asset (TTM) | 0.2714 | |
| Return on equity (TTM) | 0.4038 | |
| Revenue TTM | 443,780,000 | |
| Revenue per share TTM | 1.7740 | |
| Quarterly Revenue Growth (YOY) | -0.4120 | |
| Quarterly Earnings Growth (YOY) | 35.2850 | |
| Gross Profit (TTM) | 176,619,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 20.4348 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 4.1260 | |
| Revenue Enterprise Value | 7.2339 | |
| EBITDA Enterprise Value | 10.3926 | |
| Shares | ||
| Shares Outstanding | 281,580,992 | |
| Shares Float | 178,930,821 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 30.25 | |
| Institutions (%) | 43.63 | |
10/04 09:00 EST - businesswire.com
AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024.
AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024.
09/26 16:05 EST - businesswire.com
AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024.
AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024.
08/23 04:43 EST - seekingalpha.com
AbCellera: A Waiting Game With High Uncertainty
AbCellera's Q2 2024 revenue declined by 27% year-over-year to $7.3 million. The company's net loss widened to $36.9 million due to increased R&D expenses. AbCellera's cash and marketable securities totaled $697.6 million, with total liquidity exceeding $900 million.
AbCellera: A Waiting Game With High Uncertainty
AbCellera's Q2 2024 revenue declined by 27% year-over-year to $7.3 million. The company's net loss widened to $36.9 million due to increased R&D expenses. AbCellera's cash and marketable securities totaled $697.6 million, with total liquidity exceeding $900 million.
08/06 19:15 EST - zacks.com
AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Misses Revenue Estimates
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.11 per share a year ago.
AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Misses Revenue Estimates
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.11 per share a year ago.
07/30 08:49 EST - 247wallst.com
5 Penny Stocks With 250% Upside in 1 Year According to Wall Street
Penny stocks represent an interesting investment opportunity.
5 Penny Stocks With 250% Upside in 1 Year According to Wall Street
Penny stocks represent an interesting investment opportunity.
07/21 05:37 EST - fool.com
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
The Baker brothers acquired millions of shares of AbCellera Biologics and Fate Therapeutics during the first months of 2024. AbCellera Biologics is a drug discovery business with a hand in more than a dozen experimental drugs in clinical-stage development.
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
The Baker brothers acquired millions of shares of AbCellera Biologics and Fate Therapeutics during the first months of 2024. AbCellera Biologics is a drug discovery business with a hand in more than a dozen experimental drugs in clinical-stage development.
07/09 13:01 EST - zacks.com
AbCellera Biologics (ABCL) Upgraded to Buy: Here's What You Should Know
AbCellera Biologics (ABCL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AbCellera Biologics (ABCL) Upgraded to Buy: Here's What You Should Know
AbCellera Biologics (ABCL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
06/25 16:05 EST - businesswire.com
AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024.
AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024.
06/13 05:40 EST - fool.com
Down 57%, Is AbCellera Biologics a Buy on the Dip?
AbCellera Biologics is a biotechnology company built to discover new antibodies for other drugmakers. The stock has fallen more than 90% from its all-time high and by 57% from a peak it set last summer.
Down 57%, Is AbCellera Biologics a Buy on the Dip?
AbCellera Biologics is a biotechnology company built to discover new antibodies for other drugmakers. The stock has fallen more than 90% from its all-time high and by 57% from a peak it set last summer.
05/28 16:05 EST - businesswire.com
AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024.
AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024.
05/13 06:00 EST - investorplace.com
3 Stock Gems Hiding in the Nasdaq
With the technology benchmark Nasdaq index encountering some choppy weather since April, speculators may want to consider undervalued Nasdaq stocks. Granted, it's always risky betting on enterprises that haven't caught other people's attention.
3 Stock Gems Hiding in the Nasdaq
With the technology benchmark Nasdaq index encountering some choppy weather since April, speculators may want to consider undervalued Nasdaq stocks. Granted, it's always risky betting on enterprises that haven't caught other people's attention.
05/07 23:00 EST - seekingalpha.com
AbCellera Biologics Inc. (ABCL) Q1 2024 Earnings Call Transcript
AbCellera Biologics Inc. (NASDAQ:ABCL ) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants Tryn Stimart - Chief Legal & Compliance Officer Carl Hansen - President, Chief Executive Officer Andrew Booth - Chief Financial Officer Conference Call Participants Andrea Tan - Goldman Sachs Jacqueline Kisa - TD Securities Scott Schoenhaus - KeyBanc Stephen Willey - Stifel Operator Good afternoon and welcome to AbCellera's Q1, 2024 Business Update Conference Call. My name is Harry and I will facilitate the audio portion of today's interactive broadcast.
AbCellera Biologics Inc. (ABCL) Q1 2024 Earnings Call Transcript
AbCellera Biologics Inc. (NASDAQ:ABCL ) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants Tryn Stimart - Chief Legal & Compliance Officer Carl Hansen - President, Chief Executive Officer Andrew Booth - Chief Financial Officer Conference Call Participants Andrea Tan - Goldman Sachs Jacqueline Kisa - TD Securities Scott Schoenhaus - KeyBanc Stephen Willey - Stifel Operator Good afternoon and welcome to AbCellera's Q1, 2024 Business Update Conference Call. My name is Harry and I will facilitate the audio portion of today's interactive broadcast.
05/07 19:06 EST - zacks.com
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.14 per share a year ago.
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.14 per share a year ago.
05/07 16:05 EST - businesswire.com
AbCellera Reports Q1 2024 Business Results
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q1 2024 Business Results.
AbCellera Reports Q1 2024 Business Results
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q1 2024 Business Results.
05/01 09:00 EST - businesswire.com
AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies.
AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies.
04/30 11:06 EST - zacks.com
Analysts Estimate AbCellera Biologics Inc. (ABCL) to Report a Decline in Earnings: What to Look Out for
AbCellera Biologics (ABCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate AbCellera Biologics Inc. (ABCL) to Report a Decline in Earnings: What to Look Out for
AbCellera Biologics (ABCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
04/08 12:05 EST - businesswire.com
AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024.
AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024.
04/03 16:05 EST - businesswire.com
AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) will announce its first quarter 2024 financial results on Tuesday, May 7, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologic.
AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) will announce its first quarter 2024 financial results on Tuesday, May 7, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologic.
03/27 16:30 EST - investorplace.com
The 7 Best Penny Stocks to Buy in Q2 2024
This month in March is a great time to pick up shares in these best penny stocks to buy. I chose the companies due to their strong fundamentals and potential for significant upside.
The 7 Best Penny Stocks to Buy in Q2 2024
This month in March is a great time to pick up shares in these best penny stocks to buy. I chose the companies due to their strong fundamentals and potential for significant upside.
03/19 16:05 EST - businesswire.com
AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the Bloom Burton Healthcare Conference on Tuesday, April 16, 2024, at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time). A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the presentation. About AbCellera Biologics Inc.
AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the Bloom Burton Healthcare Conference on Tuesday, April 16, 2024, at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time). A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the presentation. About AbCellera Biologics Inc.